CARLSBAD, Calif.--Invitrogen named two new board members to guide the development of a new division focused on applying Invitrogen's gene cloning and expression technologies to enable functional genomics studies for drug discovery, diagnostic development, and crop improvement. James Glynn was appointed senior vice-president and member of the board of directors, and Lewis Shuster, chief financial officer of Pharmacopeia, was also named to the board.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.